Matthew J Price

Summary

Affiliation: Scripps Clinic
Country: USA

Publications

  1. ncbi Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California 92037, USA
    J Am Coll Cardiol 59:1928-37. 2012
  2. ncbi Genetic considerations
    Matthew J Price
    Cardiac Catheterization Laboratory, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA, USA
    Adv Cardiol 47:100-13. 2012
  3. ncbi Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial
    Matthew J Price
    Scripps Clinic and Scripps Translational Science Institute, La Jolla, California, USA
    J Am Coll Cardiol 59:2338-43. 2012
  4. ncbi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, 10666 North Torrey Pines Road, Maildrop S1056, La Jolla, CA 92037, USA
    Eur Heart J 29:992-1000. 2008
  5. ncbi New antiplatelet therapies in development
    Matthew J Price
    Cardiac Catheterization Laboratory, Division of Cardiovascular Disease, Scripps Clinic, 10666 North Torrey Pines Road, Maildrop S1056, La Jolla, CA 92037, USA
    Am J Health Syst Pharm 65:S11-5; quiz S16-8. 2008
  6. ncbi Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial
    Matthew J Price
    Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA, USA
    Circulation 124:1132-7. 2011
  7. ncbi The off- versus on-label use of medical devices in interventional cardiovascular medicine: clarifying the ambiguity between regulatory labeling and clinical decision-making, Part 1: PCI
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Catheter Cardiovasc Interv 72:500-4. 2008
  8. ncbi Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic and Scripps Advanced Clinical Trials, La Jolla, CA, USA
    Am Heart J 157:818-24, 824.e1. 2009
  9. ncbi Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Am J Cardiol 103:1339-43. 2009
  10. ncbi Evaluation of clopidogrel responsiveness after drug-eluting stent implantation
    M J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA 92037, USA
    Minerva Cardioangiol 57:657-66. 2009

Collaborators

Detail Information

Publications39

  1. ncbi Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California 92037, USA
    J Am Coll Cardiol 59:1928-37. 2012
    ..This study sought to evaluate the influence of single nucleotide polymorphisms (SNPs) on the pharmacodynamic effect of high- or standard-dose clopidogrel after percutaneous coronary intervention (PCI)...
  2. ncbi Genetic considerations
    Matthew J Price
    Cardiac Catheterization Laboratory, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA, USA
    Adv Cardiol 47:100-13. 2012
    ....
  3. ncbi Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial
    Matthew J Price
    Scripps Clinic and Scripps Translational Science Institute, La Jolla, California, USA
    J Am Coll Cardiol 59:2338-43. 2012
    ..The goal of this study was to assess the offset of the antiplatelet effects of prasugrel and clopidogrel...
  4. ncbi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, 10666 North Torrey Pines Road, Maildrop S1056, La Jolla, CA 92037, USA
    Eur Heart J 29:992-1000. 2008
    ....
  5. ncbi New antiplatelet therapies in development
    Matthew J Price
    Cardiac Catheterization Laboratory, Division of Cardiovascular Disease, Scripps Clinic, 10666 North Torrey Pines Road, Maildrop S1056, La Jolla, CA 92037, USA
    Am J Health Syst Pharm 65:S11-5; quiz S16-8. 2008
    ..The efficacy and safety of new antiplatelet therapies, as well as antiplatelet therapies in development, are reviewed...
  6. ncbi Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial
    Matthew J Price
    Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA, USA
    Circulation 124:1132-7. 2011
    ..The aim of this analysis was to examine the relationship between outcomes and OTR over the course of the trial...
  7. ncbi The off- versus on-label use of medical devices in interventional cardiovascular medicine: clarifying the ambiguity between regulatory labeling and clinical decision-making, Part 1: PCI
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Catheter Cardiovasc Interv 72:500-4. 2008
    ....
  8. ncbi Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic and Scripps Advanced Clinical Trials, La Jolla, CA, USA
    Am Heart J 157:818-24, 824.e1. 2009
    ....
  9. ncbi Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Am J Cardiol 103:1339-43. 2009
    ..0% vs 0%; p = 0.016). In conclusion, our findings support the hypothesis that clopidogrel nonresponsiveness is primarily the result of genetic mechanisms and factors that may influence activity of the cytochrome P-450 system...
  10. ncbi Evaluation of clopidogrel responsiveness after drug-eluting stent implantation
    M J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA 92037, USA
    Minerva Cardioangiol 57:657-66. 2009
    ..Several ongoing randomized clinical trials are testing the safety and efficacy of individualized antiplatelet therapy based on platelet function testing to reduce ischemic events after PCI with drug-eluting stents...
  11. ncbi Utility of on-line three-dimensional transesophageal echocardiography during percutaneous atrial septal defect closure
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Catheter Cardiovasc Interv 75:570-7. 2010
    ..We present several cases of percutaneous ASD closure guided by on-line 3D TEE imaging that highlight the potential advantages of this new imaging technology...
  12. ncbi Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists
    Matthew J Price
    Division of Cardiology, University of Texas Medical School at Houston, Memorial Hermann Hospital Heart and Vascular Institute at the Texas Medical Center, USA
    Biomark Med 5:43-51. 2011
    ..Over the past few years, a wealth of data have helped bring this promise closer to reality, and upcoming clinical trials of platelet function testing could at last bring personalized medicine into routine clinical practice...
  13. ncbi Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial
    Matthew J Price
    Scripps Clinic, La Jolla, California, USA
    JAMA 305:1097-105. 2011
    ..High platelet reactivity while receiving clopidogrel has been linked to cardiovascular events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue is not well defined...
  14. ncbi Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Am J Cardiol 102:790-5. 2008
    ..A strategy of individual platelet function monitoring should be examined in patients requiring cardiac surgery after clopidogrel loading...
  15. ncbi Rescue percutaneous coronary intervention early after coronary artery bypass grafting in the drug-eluting stent era
    Matthew J Price
    Department of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Am J Cardiol 97:789-91. 2006
    ....
  16. ncbi Intracoronary radiation therapy for multi-drug resistant in-stent restenosis: initial clinical experience
    Matthew J Price
    Department of Cardiovascular Disease, Scripps Clinic, La Jolla, California 92014, USA
    Catheter Cardiovasc Interv 69:132-4. 2007
    ..Our findings support the further study of this management approach...
  17. ncbi Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Am J Cardiol 98:681-4. 2006
    ..A point-of-care assay can identify subjects who may recover platelet function before 5 days after discontinuation or, in contrast, have persistent PI despite discontinuation...
  18. ncbi Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity
    Colin M Barker
    Division of Cardiology, University of Texas Medical School at Houston, Houston, Texas 77030, USA
    JACC Cardiovasc Interv 3:1001-7. 2010
    ..The objective of this study was to evaluate the antiplatelet effect of clopidogrel 150 mg/day in patients with high on-treatment reactivity (OTR) and to further assess this effect according to CYP2C19 genotype...
  19. ncbi Utility of three-dimensional reconstruction of coronary angiography to guide percutaneous coronary intervention
    Raghava R Gollapudi
    Division of Cardiovascular Diseases, Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA
    Catheter Cardiovasc Interv 69:479-82. 2007
    ....
  20. ncbi Early- and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure
    Steve S Lee
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Am J Cardiol 98:1345-8. 2006
    ..7%. In conclusion, at medium-term follow-up, PES implantation for SES failure appears to be safe and effective, although efficacy is decreased in the setting of total occlusions, greater residual diameter stenosis, and longer PESs...
  21. ncbi Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial)
    Rafael Valencia
    Department of Cardiovascular Diseases, Scripps Clinic, La Jolla, California
    Am J Cardiol 100:1099-102. 2007
    ..10). In conclusion, during elective PCI, a strategy of aggressive antiplatelet therapy using aspirin, clopidogrel, and eptifibatide without anticoagulant therapy appears to decrease bleeding complications...
  22. ncbi A novel technique for ultra-low contrast administration during angiography or intervention
    Keshav R Nayak
    Scripps Clinic, La Jolla, CA, USA
    Catheter Cardiovasc Interv 75:1076-83. 2010
    ..We report a novel technique designed to deliver ultra-low (<15 cm(3)) volume contrast to patients with chronic kidney disease undergoing coronary angiography and PCI...
  23. ncbi Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization
    David E Kandzari
    Division of Cardiovascular Disease, Scripps Clinic, La Jolla, California 92037, USA
    JACC Cardiovasc Interv 2:1279-85. 2009
    ....
  24. ncbi Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction
    Raj R Makkar
    Division of Cardiology and Hematology, Cedars Sinai Medical Center, and David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Cardiovasc Pharmacol Ther 10:225-33. 2005
    ..We investigated the efficacy of directly injected allogenic bone marrow-derived mesenchymal stem cells in improving left ventricular function in a porcine model of myocardial infarction...
  25. ncbi Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization
    Matthew J Price
    Division of Cardiovascular Disease, Scripps Clinic, La Jolla, California 92037, USA
    J Am Coll Cardiol 47:871-7. 2006
    ..Restenosis is usually focal, most often involves the LCX ostium, and often occurs without symptoms...
  26. ncbi The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors
    Matthew J Price
    Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA, USA
    Rev Cardiovasc Med 12:1-12. 2011
    ....
  27. ncbi Antiplatelet therapy in acute coronary syndromes
    Colin M Barker
    Division of Cardiovascular Diseases, Scripps Clinic, 10666 North Torrey Pines Road, Maildrop S1056, La Jolla, CA 92037, USA
    Curr Cardiol Rep 10:327-33. 2008
    ..Newer thienopyridine and non-thienopyridine P2Y12 receptor agonists offer the advantages of a rapid onset of action and greater and more consistent platelet inhibition...
  28. ncbi Monitoring platelet function to reduce the risk of ischemic and bleeding complications
    Matthew J Price
    Cardiac Catheterization Laboratory, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Am J Cardiol 103:35A-39A. 2009
    ..The use of platelet function monitoring to guide the timing of surgery after the discontinuation of antiplatelet therapy also merits further study...
  29. ncbi Clinical outcomes following predilation with a novel 1.25-mm diameter angioplasty catheter
    David E Kandzari
    Scripps Clinic, Division of Cardiovascular Diseases, La Jolla, California, USA
    Catheter Cardiovasc Interv 77:510-4. 2011
    ..An unmet need is represented in angioplasty catheters that permit the predilation stage of treating complex coronary anatomy oftentimes not amenable to conventional device therapies...
  30. ncbi A multicenter, randomized, dose-finding study of gamma intracoronary radiation therapy to inhibit recurrent restenosis after stenting
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    J Invasive Cardiol 18:169-73. 2006
    ..An increase in the currently recommended gamma radiation dose prescription from 14 Gy to 17 Gy should be strongly considered...
  31. ncbi Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Catheter Cardiovasc Interv 65:208-11. 2005
    ..By 7-month follow-up, event-free survival is limited primarily by disease in nontarget vessels...
  32. ncbi Three-year outcome of drug-eluting stent implantation for coronary artery bifurcation lesions
    Curtiss T Stinis
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA 92037, USA
    Catheter Cardiovasc Interv 75:309-14. 2010
    ..To compare the very long-term clinical outcomes of bifurcation lesions using the crush and the simultaneous kissing stent (SKS) techniques...
  33. ncbi Clopidogrel desensitization after drug-eluting stent placement
    Karl F von Tiehl
    Division of Allergy, Asthma and Immunology, Scripps Clinic and Scripps Green Hospital, La Jolla, California, USA
    J Am Coll Cardiol 50:2039-43. 2007
    ..We hypothesized that a standardized outpatient clopidogrel desensitization protocol would be safe and effective...
  34. ncbi Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization
    Paul S Teirstein
    Division of Cardiovascular Disease, Scripps Clinic, La Jolla, California, USA
    Am J Cardiol 97:1076-81. 2006
    ..It would be appropriate to restudy this renal vasodilator for the prevention of contrast nephropathy, using selective IR delivery...
  35. ncbi Left main percutaneous coronary intervention
    Paul S Teirstein
    Scripps Clinic and Scripps Translational Science Institute, La Jolla, California
    J Am Coll Cardiol 60:1605-13. 2012
    ..Herein, we review the current data comparing PCI with CABG for left main disease, summarize recent guideline recommendations, and provide an update on technical considerations that may optimize clinical outcomes in left main PCI...
  36. ncbi Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties
    Matthew J Price
    Division of Cardiology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, USA
    Int J Cardiol 111:231-9. 2006
    ..Since there is no need for immune suppression or clinical expertise, IV infusion of MSCs may expand the potential clinical application of stem cell therapy...
  37. ncbi Stem cell repair of infarcted myocardium: an overview for clinicians
    James S Forrester
    Division of Cardiology, Cedars-Sinai Medical Center and Department of Medicine, UCLA School of Medicine, Los Angeles, Calif 90048, USA
    Circulation 108:1139-45. 2003
  38. ncbi A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease
    Giuseppe G L Biondi-Zoccai
    Interventional Cardiology, Division of Cardiology, University of Turin, Turin, Italy
    Am Heart J 155:274-83. 2008
    ..Drug-eluting stent (DES) implantation has been recently reported in patients with ULM but with unclear results. We systematically reviewed outcomes of percutaneous DES implantation in ULM...
  39. ncbi The effect of granulocyte colony stimulating factor on regional and global myocardial function in the porcine infarct model
    Steve S Lee
    Division of Cardiology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, United States
    Int J Cardiol 116:225-30. 2007
    ....